TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23795312

Group type: EXPERIMENTAL
Intervention: Extended Release Niacin (ERN) titrated from 500mg/night to 1500mg/night
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 17
Study: 21087857

Group type: EXPERIMENTAL
Intervention: Screening group (biennial PSA screening)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not invited to screening)
Number of subjects: 20
Study: 19854593

Group type: EXPERIMENTAL
Intervention: Short-term aerobic training (10 sessions of submaximal aerobic cycling, 35 min for each session, 3 times a week)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Short-term aerobic training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study: 17100739

Group type: EXPERIMENTAL
Intervention: Topical tacalcitol cream with 308-nm monochromatic excimer light (MEL) therapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Vehicle with 308-nm monochromatic excimer light (MEL) therapy
Number of subjects: 38
Study: 16224678

Group type: EXPERIMENTAL
Intervention: NexGen LPS Flex mobile knee prosthesis
Number of subjects: 60

Group type: COMPARATOR
Intervention: NexGen LPS
Number of subjects: 60
Study: 12385678

Group type: EXPERIMENTAL
Intervention: AMX/CA 2000/125 mg bid
Number of subjects: 5531

Group type: COMPARATOR
Intervention: Comparators (levofloxacin 500 mg od, clarithromycin 500 mg bid, AMX/CA 875/125 mg bid and tid, AMX/CA 1000/125 mg tid)
Number of subjects: 5531

Group type: COMPARATOR
Intervention: Comparators (for PRSP)
Number of subjects: 5531
Study: 10385761

Group type: EXPERIMENTAL
Intervention: Reteplase (2 intravenous bolus injections of 10 U 30 minutes apart)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Alteplase (intravenous infusion of a total dose of 100 mg over a 2‐hour period, including an initial 10‐mg bolus)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 36

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Reteplase and Alteplase
Number of subjects: 36
Study: 8789581

Group type: EXPERIMENTAL
Intervention: 3 hours of passive recovery between exercise sessions (3 on 1)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Approximately 24 hours of recovery between exercise sessions (3 con)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Familiarisation trials
Number of subjects: 9
Study: 2174446

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg per day for 3 weeks
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 7004471

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 63
Study: 31958480

Group type: EXPERIMENTAL
Intervention: Food distractors
Number of subjects: 51

Group type: COMPARATOR
Intervention: Toy distractors
Number of subjects: 51
Study: 30882135

Group type: EXPERIMENTAL
Intervention: Intervention arm (alcohol screening and brief advice)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Process evaluation
Number of subjects: 229
Study: 28439109

Group type: EXPERIMENTAL
Intervention: Carfilzomib–lenalidomide–dexamethasone (ASPIRE)
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Carfilzomib–dexamethasone (ENDEAVOR)
Number of subjects: 984
Study: 26105170

Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily (arm 1)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Raltegravir 800 mg twice daily initially then 400 mg twice daily after 4 weeks (arm 2)
Number of subjects: 37
Study: 24315882

Group type: EXPERIMENTAL
Intervention: Ramosetron (5 μg oral, once daily for 12 weeks)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Placebo (once daily for 12 weeks)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Ramosetron
Number of subjects: 296
Study: 21627752

Group type: EXPERIMENTAL
Intervention: Dorsal slit method
Number of subjects: 5142

Group type: COMPARATOR
Intervention: Sleeve method
Number of subjects: 5142

Group type: EXPERIMENTAL
Intervention: Bipolar cautery
Number of subjects: 5142
Study: 19250979

Group type: EXPERIMENTAL
Intervention: Diabetes communication system using mobile phones and patient/physician portals
Number of subjects: 260

Group type: COMPARATOR
Intervention: Usual care from primary care physicians (PCPs)
Number of subjects: 260
Study: 17559787

Group type: EXPERIMENTAL
Intervention: Posterior Chamber Intraocular Lens (PC IOL)
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Anterior Chamber Intraocular Lens (AC IOL)
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Insufficient Capsular Support (ICS)
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Nonvitreous Presentation (NVP)
Number of subjects: 1102
Study: 15608392

Group type: EXPERIMENTAL
Intervention: CEOP‐E regimen (cyclophosphamide 750 mg/m², epirubicin 50 mg/m², vincristine 2 mg, etoposide 80 mg/m² on day 1 and oral prednisone 100 mg on days 1 to 5)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: CEOP‐E regimen
Number of subjects: 51
Study: 12000411

Group type: EXPERIMENTAL
Intervention: Community health intervention (hospital and home visits, telephone support for 6 months)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Community health intervention
Number of subjects: 41
Study: 9846858

Group type: EXPERIMENTAL
Intervention: Sucrose polyester (60 mL)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Digestible fat
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 8
Study: 8081594

Group type: EXPERIMENTAL
Intervention: Actiferrin Compositum (1 capsule per day from 36th week, increasing to 2 capsules per day until childbirth)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (57 non-anaemic not treated pregnant women)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Actiferrin Compositum
Number of subjects: 84
Study: 2682862

Group type: EXPERIMENTAL
Intervention: Broncho‐Vaxom (BV)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 4609544

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 94

Group type: COMPARATOR
Intervention: Other antibiotics
Number of subjects: 94
Study: 31994716

Group type: EXPERIMENTAL
Intervention: Givosiran (subcutaneously administered)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Givosiran (once monthly dosing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Givosiran (once quarterly dosing)
Number of subjects: 0
Study: 29396658

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 488
Study: 26779911

Group type: COMPARATOR
Intervention: US‐CNPB
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CT‐ANPB
Number of subjects: 150
Study: 24886238

Group type: EXPERIMENTAL
Intervention: Nurse-moderated group-based internet intervention
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: Single clinic-based appointment plus nurse-moderated group-based internet intervention
Number of subjects: 819

Group type: COMPARATOR
Intervention: Single home-visit with subsequent standard services
Number of subjects: 819
Study: 22268662

Group type: EXPERIMENTAL
Intervention: Sphincter training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (matched patients)
Number of subjects: 22
Study: 20306535

Group type: EXPERIMENTAL
Intervention: Garlic capsules (656 mg daily)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Olive oil capsules (656 mg daily) - Control
Number of subjects: 34
Study: 18361977

Group type: EXPERIMENTAL
Intervention: Neural vision enhancement technology (NVC, NeuroVision, Inc.)
Number of subjects: 20
Study: 16197584

Group type: EXPERIMENTAL
Intervention: Bicarbonated mineral water 2
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bicarbonated mineral water 1
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low mineral water
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bicarbonated mineral waters (1 and 2)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All water types
Number of subjects: 18
Study: 12182215

Group type: EXPERIMENTAL
Intervention: DEF
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: ADQ
Number of subjects: 17
Study: 10598763

Group type: EXPERIMENTAL
Intervention: Normal-mode ruby laser treatment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Shaved test area (control)
Number of subjects: 17
Study: 7795836

Group type: EXPERIMENTAL
Intervention: Potassium supplementation (60 mmol/d)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study: 2309177

Group type: EXPERIMENTAL
Intervention: Ampicillin (2 g) plus cloxacillin (2 g) as a single-dose infusion after division of the cord
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benzylpenicillin (2 g)
Number of subjects: 0
Study: 6169424

Group type: EXPERIMENTAL
Intervention: Whole-brain irradiation schedule of 2000 rad in one week
Number of subjects: 1830

Group type: EXPERIMENTAL
Intervention: Whole-brain irradiation schedule of 4000 rad in four weeks
Number of subjects: 1830
Study: 30582271

Group type: EXPERIMENTAL
Intervention: Valsartan/Amlodipine 80/5 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Nifedipine GITS 30 mg
Number of subjects: 150
Study: 29962098

Group type: EXPERIMENTAL
Intervention: Tibial internal rotation (IR) group performing leg press activity with tibia in maximal IR
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neutral rotation (NR) group performing leg press activity with tibia in neutral rotation
Number of subjects: 60
Study: 27072821

Group type: EXPERIMENTAL
Intervention: Mucin-secreting papillary renal cell carcinoma (PRCCM) tumors
Number of subjects: 7
Study: 24975713

Group type: EXPERIMENTAL
Intervention: Transperitoneal laparoscopic nephrectomy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Retroperitoneoscopic nephrectomy
Number of subjects: 62
Study: 22017815

Group type: EXPERIMENTAL
Intervention: Low-GI breakfast
Number of subjects: 52

Group type: COMPARATOR
Intervention: High-GI breakfast
Number of subjects: 52
Study: 20978060

Group type: EXPERIMENTAL
Intervention: Patient decision aid (interactive booklet and DVD)
Number of subjects: 572

Group type: COMPARATOR
Intervention: Control group (standard information for Australian national bowel screening programme)
Number of subjects: 572
Study: 18471658

Group type: EXPERIMENTAL
Intervention: Randomized trials
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: Nonrandomized studies
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: Case reports
Number of subjects: 946
Study: 16154016

Group type: EXPERIMENTAL
Intervention: Amlodipine 5-10 mg adding perindopril 4-8 mg as required
Number of subjects: 19257
Study: 11849191

Group type: EXPERIMENTAL
Intervention: i.v. ARTS (120 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: i.m. ARTS (120 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: rectal DHA (160 mg)
Number of subjects: 12
Study: 11084179

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Copper T380A intrauterine device
Number of subjects: 50
Study: 9188111

Group type: EXPERIMENTAL
Intervention: Self made introducer for LMA placement
Number of subjects: 251
Study: 1416875

Group type: EXPERIMENTAL
Intervention: Isepamicin (7.5 mg/kg) with piperacillin (4 g every 12 h for four doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gentamicin (2 mg/kg) with piperacillin (4 g every 12 h for four doses)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Gentamicin alone
Number of subjects: 12
Study: 2991817

Group type: EXPERIMENTAL
Intervention: Org 2766 (synthetic ACTH 4-9 analog), administered for 6 months
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 31163232

Group type: EXPERIMENTAL
Intervention: 3-dimensionally printed MMS model with standardized education (SE)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standardized education (SE) alone
Number of subjects: 82
Study: 29054507

Group type: EXPERIMENTAL
Intervention: Web-based teaching tool
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional didactic teaching
Number of subjects: 40
Study: 26414912

Group type: EXPERIMENTAL
Intervention: one tablet weekly (one/week)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: one tablet twice weekly (two/week)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: two tablets twice weekly (four/week)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: one tablet daily (seven/week)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: ≥4/week regimens
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: All analytes in serum and PBMCs
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Steady-state daily dosing serum TFV and PBMC TFV-DP
Number of subjects: 49
Study: 25363219

Group type: EXPERIMENTAL
Intervention: Pirfenidone 2403 mg/day
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Pirfenidone (from CAPACITY study)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo (from CAPACITY study)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 178
Study: 23584329

Group type: EXPERIMENTAL
Intervention: Active recovery (ballistic bench throws 1x3 repetitions at 30% 1-RM bench press)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Passive recovery (8 minutes of rest)
Number of subjects: 36
Study: 20940646

Group type: EXPERIMENTAL
Intervention: Combined treatment (manual massage and compression)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Compression treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Passive recovery
Number of subjects: 32
Study: 18936064

Group type: EXPERIMENTAL
Intervention: Parenteral steroids before planned extubation
Number of subjects: 1923

Group type: EXPERIMENTAL
Intervention: Multidose regimen of steroids
Number of subjects: 1923

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1923
Study: 16638415

Group type: EXPERIMENTAL
Intervention: Alefacept 15 mg administered subcutaneously (SC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Alefacept 15 mg administered intramuscularly (IM)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Alefacept SC
Number of subjects: 50

Group type: COMPARATOR
Intervention: Alefacept IM
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Alefacept SC and IM
Number of subjects: 50
Study: 12889718

Group type: EXPERIMENTAL
Intervention: RA+HQ+FA (tretinoin 0.05%, hydroquinone 4.0%, fluocinolone acetonide 0.01%)
Number of subjects: 641

Group type: COMPARATOR
Intervention: Dual-combination agents (RA+HQ, RA+FA, HQ+FA)
Number of subjects: 641
Study: 11109969

Group type: EXPERIMENTAL
Intervention: Starting dose of recombinant follicle stimulating hormone (FSH) followed by highly purified urinary FSH
Number of subjects: 46

Group type: COMPARATOR
Intervention: Highly purified urinary FSH alone
Number of subjects: 46
Study: 8630607

Group type: EXPERIMENTAL
Intervention: Home pressure support device
Number of subjects: 7

Group type: COMPARATOR
Intervention: Intensive care pressure support device
Number of subjects: 7
Study: 1426207

Group type: EXPERIMENTAL
Intervention: Zardaverine (6 mg total dose, 4 puffs at 15 min intervals)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zardaverine
Number of subjects: 12
Study: 31627016

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccination (PCV) post-2010
Number of subjects: 800

Group type: COMPARATOR
Intervention: Pneumococcal polysaccharide vaccine (PPV) pre-2010
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccination (PCV) post-2010 in auto‐HSCT
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccination (PCV) post-2010 in allo‐HSCT
Number of subjects: 800
Study: 31538304

Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF)
Number of subjects: 696
Study: 27823981

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 30
Study: 25395609

Group type: EXPERIMENTAL
Intervention: New amino acid-based formula (AAF)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Commercial amino acid-based formula (AAF)
Number of subjects: 33
Study: 24114082

Group type: EXPERIMENTAL
Intervention: Fixed condition sequence
Number of subjects: 7

Group type: COMPARATOR
Intervention: Random condition sequence
Number of subjects: 7
Study: 21273036

Group type: EXPERIMENTAL
Intervention: Pantoprazole (40 mg twice daily for 7 days)
Number of subjects: 665

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 665
Study: 19148687

Group type: EXPERIMENTAL
Intervention: Autogenous iliac crest cancellous bone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Allogenic cancellous bone graft
Number of subjects: 40
Study: 17924872

Group type: EXPERIMENTAL
Intervention: 5 g of cinnamon (OGTT(cin))
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 5 g of cinnamon taken 12 h before (OGTT(cin12hpre))
Number of subjects: 7

Group type: COMPARATOR
Intervention: 5 g placebo (OGTT(control))
Number of subjects: 7
Study: 15194892

Group type: EXPERIMENTAL
Intervention: 7-day recall period
Number of subjects: 7674

Group type: EXPERIMENTAL
Intervention: 4-week recall period
Number of subjects: 7674

Group type: EXPERIMENTAL
Intervention: Version 3 interview
Number of subjects: 7674

Group type: EXPERIMENTAL
Intervention: 2-week recall period
Number of subjects: 7674
Study: 12351302

Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT) and Laryngeal Mask Airway (LMA)
Number of subjects: 50
Study: 9537699

Group type: EXPERIMENTAL
Intervention: Calcium-restricted diet (500 mg/day, oxalate-rich products discouraged, normalization of animal protein and sodium)
Number of subjects: 25

Group type: COMPARATOR
Intervention: No restrictions (Control group)
Number of subjects: 25
Study: 7863142

Group type: EXPERIMENTAL
Intervention: Diet group
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Physical exercise group
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Diet and physical exercise group
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 158
Study: 2688437

Group type: EXPERIMENTAL
Intervention: Pulsatile glucagon and continuous insulin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pulsatile delivery of both insulin and glucagon
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Both insulin and glucagon delivered intermittently and out of phase
Number of subjects: 6

Group type: COMPARATOR
Intervention: Continuous infusion of insulin and glucagon
Number of subjects: 6
Study: 4443501

Group type: EXPERIMENTAL
Intervention: 2 treatment strategies
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control treatment strategy
Number of subjects: 139
Study: 31601285

Group type: EXPERIMENTAL
Intervention: Medium energy turnover (ET) during energy balance (EB)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High energy turnover (ET) during energy balance (EB)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Medium energy turnover (ET) during overfeeding (OF)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High energy turnover (ET) during overfeeding (OF)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Low energy turnover (ET) during energy balance (EB)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Low energy turnover (ET) during overfeeding (OF)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Energetic restriction (ER)
Number of subjects: 9
Study: 30422156

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab (arm A)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Chemotherapy plus cetuximab (arm B)
Number of subjects: 132
Study: 29051274

Group type: EXPERIMENTAL
Intervention: Immediate-release oral morphine
Number of subjects: 20
Study: 26200526

Group type: EXPERIMENTAL
Intervention: Anterior repositioning occlusal splints (ARS) with counseling
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nociceptive Trigeminal Inhibition Clenching Suppression System devices (NTI‐tss) with counseling
Number of subjects: 60

Group type: COMPARATOR
Intervention: Counseling for behavioral changes and self-care (Control group)
Number of subjects: 60
Study: 23270921

Group type: EXPERIMENTAL
Intervention: Video plus verbal feedback
Number of subjects: 54

Group type: COMPARATOR
Intervention: Verbal feedback
Number of subjects: 54

Group type: COMPARATOR
Intervention: Experiential feedback
Number of subjects: 54
Study: 21206931

Group type: EXPERIMENTAL
Intervention: Pomegranate mouthrinse
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse
Number of subjects: 30

Group type: COMPARATOR
Intervention: Distilled water (placebo)
Number of subjects: 30
Study: 19435520

Group type: EXPERIMENTAL
Intervention: Clinically integrated e‐learning course
Number of subjects: 61

Group type: COMPARATOR
Intervention: Traditional lecture based course
Number of subjects: 61
Study: 17366451

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHP)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Artesunate-amodiaquine (AAQ)
Number of subjects: 334
Study: 15541529

Group type: EXPERIMENTAL
Intervention: Bimanual task
Number of subjects: 78
Study: 11673036

Group type: EXPERIMENTAL
Intervention: Subconjunctival administration of 20 mg vancomycin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous administration of 1 g b.i.d. vancomycin
Number of subjects: 100
Study: 9037131

Group type: EXPERIMENTAL
Intervention: Combined treatment with carbimazole and TSH suppressive dose of T4 for 12 months, followed by another 12 months of TSH suppressive therapy alone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Carbimazole for one year with T4 added as needed to normalize elevated TSH, no therapy during the second year
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: TSH suppressive treatment
Number of subjects: 50
Study: 7886281

Group type: EXPERIMENTAL
Intervention: All‐Erroneous KR condition (received erroneous knowledge of results during acquisition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed‐Correct KR condition (received 50 trials of correct KR followed by 25 trials of erroneous KR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erroneous KR condition (received erroneous knowledge of results during acquisition)
Number of subjects: 0